1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
- Segelmark, Mårten, et al.
(author)
-
Anti-GBM disease with a mild relapsing course and low levels ofanti-GBM autoantibodies
- 2012
-
In: Clinical Kidney Journal. - : Oxford University Press. - 2048-8505 .- 2048-8513. ; 5:6, s. 549-551
-
Journal article (peer-reviewed)abstract
- Anti-glomerular basement membrane disease (anti-GBM) is usually characterized by rapidly progressive glomerulonephritis, and when autoantibody production has ceased, relapses are rare. Here, we report a 71-year-old women diagnosed at a stage of mild renal insufficiency. Over a period of 10 years, she experienced three mild relapses with return of anti-GBM antibodies, haematuria and slight elevations in serum creatinine level. All three relapses responded to immunosuppressive therapy, and all were preceded by peaks of myeloperoxidase-antineutrophil cytoplasm antibodies (MPO-ANCA). This case shows that long-term follow-up is warranted in patients treated for anti-GBM-mediated disease, but urinary dipsticks may be sufficient for early detection of relapses.
|
|
7. |
|
|
8. |
- Westerberg, Per-Anton, 1967-, et al.
(author)
-
Oncogenic osteomalacia illustrating the effects of fibroblast factor 23 on phospahte homeostasis
- 2012
-
In: Clinical Kidney Journal. - : Oxford University Press (OUP). - 2048-8505 .- 2048-8513. ; 5:3, s. 240-243
-
Journal article (peer-reviewed)abstract
- In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.
|
|